Stock GMED GLOBUS MEDICAL, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Globus Medical, Inc.

Equities

GMED

US3795772082

Medical Equipment, Supplies & Distribution

Market Closed - Nyse
Other stock markets
 04:00:02 2024-04-26 pm EDT 		5-day change 1st Jan Change
50.55 USD +0.36% Intraday chart for Globus Medical, Inc. +0.40% -5.14%
Mar. 19 North American Morning Briefing : Stock Futures -2- DJ
Mar. 18 BTIG Upgrades Globus Medical to Buy From Neutral, Price Target is $60 MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 5,853 6,436 7,326 7,415 7,343 6,843 - -
Enterprise Value (EV) 1 5,542 6,196 6,883 6,969 7,243 5,904 5,401 4,842
P/E ratio 38.7 x 64.6 x 50.1 x 40.1 x 49.8 x 28.8 x 16.9 x 14.1 x
Yield - - - - - - - -
Capitalization / Revenue 7.45 x 8.16 x 7.65 x 7.25 x 4.68 x 2.76 x 2.58 x 2.4 x
EV / Revenue 7.06 x 7.85 x 7.18 x 6.81 x 4.62 x 2.39 x 2.04 x 1.7 x
EV / EBITDA 21.5 x 26.7 x 20.8 x 20.5 x 15.6 x 8.08 x 6.39 x 5.02 x
EV / FCF 54.7 x 45.9 x 31.4 x 66.7 x 43.8 x 5.07 x 11.1 x 8.77 x
FCF Yield 1.83% 2.18% 3.19% 1.5% 2.28% 19.7% 9.04% 11.4%
Price to Book 4.19 x 4.32 x 4.21 x 4.03 x 1.82 x 1.64 x 1.5 x 1.34 x
Nbr of stocks (in thousands) 99,409 98,676 101,471 99,843 137,793 135,372 - -
Reference price 2 58.88 65.22 72.20 74.27 53.29 50.55 50.55 50.55
Announcement Date 2/20/20 2/17/21 2/17/22 2/21/23 2/20/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 785.4 789 958.1 1,023 1,568 2,476 2,651 2,855
EBITDA 1 257.2 232.2 331.4 339.2 464.1 730.6 845.1 965.1
EBIT 1 172 111.4 172 228 133.1 447.2 546.4 633.6
Operating Margin 21.9% 14.12% 17.95% 22.29% 8.49% 18.06% 20.61% 22.19%
Earnings before Tax (EBT) 1 189.9 125.9 180.4 243 165.4 351.3 529.2 635
Net income 1 155.2 102.3 149.2 190.2 122.9 272.2 407.1 488
Net margin 19.76% 12.96% 15.57% 18.59% 7.83% 11% 15.36% 17.09%
EPS 2 1.520 1.010 1.440 1.850 1.070 1.757 2.992 3.589
Free Cash Flow 1 101.2 135.1 219.4 104.4 165.2 1,164 488 552
FCF margin 12.89% 17.13% 22.9% 10.21% 10.53% 47.01% 18.41% 19.33%
FCF Conversion (EBITDA) 39.35% 58.2% 66.19% 30.79% 35.6% 159.3% 57.75% 57.2%
FCF Conversion (Net income) 65.22% 132.12% 147.04% 54.91% 134.47% 427.57% 119.88% 113.13%
Dividend per Share 2 - - - - - - - -
Announcement Date 2/20/20 2/17/21 2/17/22 2/21/23 2/20/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 229.7 250 230.5 263.6 254.1 274.5 276.7 291.6 383.6 616.5 589.6 619 612.3 655.2 631.9
EBITDA 1 78.34 85.18 74.34 91.88 82.81 90.16 85.13 96.11 112.9 170 160.3 179.3 180.5 207.5 196.4
EBIT 1 53.33 18.2 46.44 67.78 59.7 54.03 56.4 66.21 0.404 10.12 92.6 110.3 110.5 138.7 99.28
Operating Margin 23.21% 7.28% 20.15% 25.71% 23.49% 19.68% 20.39% 22.71% 0.11% 1.64% 15.71% 17.82% 18.05% 21.17% 15.71%
Earnings before Tax (EBT) 1 54.45 19.83 48.9 70.54 61.46 62.12 63.19 74.67 2.535 25 60.3 86.07 87.97 111.3 96.28
Net income 1 47.21 15.11 38.08 54.59 47.43 50.06 49.13 57.71 0.998 15.04 47.54 66.82 68.65 85.34 74.65
Net margin 20.55% 6.04% 16.52% 20.71% 18.66% 18.24% 17.76% 19.79% 0.26% 2.44% 8.06% 10.79% 11.21% 13.03% 11.81%
EPS 2 0.4500 0.1400 0.3700 0.5300 0.4700 0.4900 0.4800 0.5700 0.0100 0.1100 0.3200 0.4238 0.4250 0.5550 0.5300
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 11/4/21 2/17/22 5/10/22 8/4/22 11/8/22 2/21/23 5/4/23 8/3/23 11/7/23 2/20/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 311 239 443 446 100 939 1,442 2,001
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 101 135 219 104 165 1,164 488 552
ROE (net income / shareholders' equity) 13.2% 7.03% 13% 10.6% 9.12% 9.69% 10.5% 11.6%
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 14.00 15.10 17.10 18.40 29.30 30.80 33.60 37.70
Cash Flow per Share 2 1.690 1.970 2.670 1.740 2.120 5.070 4.760 -
Capex 1 70.8 63.7 56.9 74 - 107 83 91
Capex / Sales 9.01% 8.07% 5.94% 7.24% - 4.32% 3.13% 3.19%
Announcement Date 2/20/20 2/17/21 2/17/22 2/21/23 2/20/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Globus Medical, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
50.55 USD
Average target price
64.89 USD
Spread / Average Target
+28.36%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

1st Jan change Capi.
GLOBUS MEDICAL, INC. Stock Globus Medical, Inc.
-5.14% 6.84B
ABBOTT LABORATORIES Stock Abbott Laboratories
-2.31% 187B
MEDTRONIC PLC Stock Medtronic plc
-3.20% 106B
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-5.04% 66.9B
DEXCOM, INC. Stock DexCom, Inc.
+0.20% 49.45B
CENCORA, INC. Stock Cencora, Inc.
+17.29% 48B
HOYA CORPORATION Stock Hoya Corporation
+4.06% 40.84B
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
+2.36% 26.25B
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+2.07% 26.48B
TERUMO CORPORATION Stock Terumo Corporation
+12.96% 24.62B
Other Medical Equipment, Supplies & Distribution
  1. Stock Market
  2. Equities
  3. GMED Stock
  4. Financials Globus Medical, Inc.